ClinicalTrials.gg
CompletedNCT01316458Updated Jun 1, 2017

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

A Phase 2 interventional study of STI571 (Glivec®) in Prostatic Neoplasm, Genital Neoplasms, Male and Neoplasms, Abdominal, sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 82 studies in Prostatic Neoplasms by Novartis — 13 open to participants now, 26 under way, 4 of them phase 3. Prostatic Neoplasms · Novartis.

Enrollment
42nd of 70
51 · median 72
Started
2003
with 5 others
Phase 2
16 of 82
none open now
Registered
34th of 82
by date

Among the 82 studies in Prostatic Neoplasms by Novartis, this one is the 42nd largest by enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2003, is one of 16 in phase 2, and was the 34th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 82 studies in Prostatic Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Prostatic Neoplasms by Novartis, or all of them as a file.
02

Study summary

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

03

Conditions studied

  • Prostatic Neoplasm
  • Genital Neoplasms, Male
  • Neoplasms, Abdominal
  • Urogenital Neoplasms
  • Genital Diseases, Male
  • Prostatic Diseases
  • Antineoplastic Agents
  • Imatinib

Keywords

  • Prostate cancer,
  • radical prostatectomy,
  • PSA rise
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • who are 18 years of age or older.
  • who have undergone radical prostatectomy within 2 years prior to PSA progression .
  • exhibiting two consecutive rises in PSA levels relative to a previous reference value, separated by 14 days.

The first measurement must occur 14 days after the reference value und must be at least 20% above the reference value. The reference value must be at least 0.4 ng/ml. The second confirmatory measurement taken 14 days after the first measurement must be greater than the first measurement.

  • with a Performance Score (KPS) greater than or equal to 90 (Appendix 5).
  • with the following hematologic lab values: ANC greater than or equal to 1500/mm3, greater than or equal to 10g/dL, greater than or equal to 100x109/L.
  • with the following biochemistry lab values: total \< 1.5 , , SGPT less than or equal to 2.5 ULN, serum creatinine less than or equal to 1.5 ULN.
  • willing to employ an effective barrier method of during the study duration and for 3 months following discontinuation of study drug (for patients of ).
  • with a of > 6 months.
  • who have provided written pursuant to local regulatory requirements prior to initiation of any study procedure.

with a Gleason Score > 6 in the prostatectomy specimen

Exclusion criteria

Exclusion Criteria:

  • with a history of another within 5 years prior to study entry, except curatively treated non-melanotic skin cancer, unless written approval is obtained by the sponsor.
  • with prior hormonal therapy
  • who require therapy with warfarin or analgesics of the morphine class or higher (see Section 3.4.4).
  • with a known diagnosis of , , or infection.
  • who have had a major surgery within 2 weeks prior to study entry.
  • with severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency ( III or IV, see Appendix 2), uncontrolled diabetes, chronic hepatic or renal disease, and active uncontrolled infection.
  • with a history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    imatinib mesylate

    Drug: STI571 (Glivec®)

Interventions

06

What researchers measure

Primary outcomes

  1. investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

    Time frame: 2 - 4 weeks

Secondary outcomes

  1. investigate the time to sustained biochemical response under the treatment of Glivec® in this patient population

    Time frame: continuous

  2. investigate duration of biochemical sustained response under the treatment with Glivec® in this patient population.

    Time frame: continuous

  3. To assess the response rates: number of patients with complete, partial and minor biochemical response and stable PSA

    Time frame: continuous

  4. To assess the time to clinical progression of this patient population treated with Glivec® at this dose and schedule.

    Time frame: continuous

  5. To descriptively characterize the safety and tolerability of Glivec® administered at this dose and schedule to this patient population.

    Time frame: continuous

07

Study locations

13 sites
  • Novartis Investigative Site
    Aachen, Germany
  • Novarts Investigative Site
    Berlin, Germany
  • Novartis Investigative Site
    Bonn, Germany
  • Novartis Investigative Site
    Borken, Germany
  • Novartis Investigative Site
    Darmstadt, Germany
  • Novartis Investigative Site
    Fürth, Germany
  • Novartis Investigative Site
    Gardelegen, Germany
  • Novarts Investigative Site
    Hamburg, Germany
  • Novartis Investigative Site
    Köln, Germany
  • Novartis Investigative Site
    Marburg, Germany
  • Novartis Investigative Site
    Ulm, Germany
  • Novartis Investigative Site
    Wesel, Germany
  • Novartis Investigative Site
    Wuppertal, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2003 and a primary completion of Jul 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2011
First posted
Mar 16, 2011
Start
Jun 2003
Primary completionActual
Jul 2010
Last update
Jun 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01316458
Responsible party
Sponsor
First posted
Mar 16, 2011
Start date
Jun 2003
Primary completion
Jul 2010
Last update
Jun 1, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion